Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-Bio-ADAURA: Mechanisms of Resistance to Neoadjuvant Osimertinib in NSCLC
KCT0011319Phase 2Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0011319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011319.